Are you a patient?

Efficacy vs ACEi (enalapril)

ENTRESTO significantly reduced risk of cardiovascular (CV) death and hospitalisation for HF vs enalapril.1-3

Time to occurrence of first hospitalisation for HF or CV death

Adapted from McMurray et al. 2014.1

Reduction in the composite primary endpoint

Reduction in the composite primary endpoint was driven equally by its individual components 1–3

Reduction in first hospitalisation

ENTRESTO significantly reduced the risk of hospitalisation for HF as early as 30 days (after first randomisation) vs enalapril (P=0.027)4,5

Quality of life benefits

ENTRESTO resulted in better patient-reported quality of life than enalapril (measured by the QoL subdomain in the in KCCQ score at month 8, P=0.0001)6

More patients had an improvement in NYHA class with ENTRESTO than enalapril (post-hoc analysis at
8 months, OR (95% CI): 1.34 (1.13-1.58) P=0.00067

ACEi = angiotensin-converting enzyme inhibitor; ARR = absolute risk reduction; CI = confidence interval; HR = hazard ratio; QoL = quality of life; KCCQ = Kansas City Cardiomyopathy Questionnaire; NYHA = New York Heart Association; OR = odds ratio

References

  1. McMurray JJV, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371(11):993–1004.
  2. ENTRESTO Summary of Product Characteristics.
  3. Novartis Pharmaceuticals. Data on file [LCZ15-C025-266a], October 2015.
  4. Packer M, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015;131(1):54–61.
  5. Novartis Pharmaceuticals. Data on file [LCZ15-C025-1128] October 2015.
  6. Novartis Pharmaceuticals. Data on file [LCZ15-C025-272] October 2015.
  7. Novartis Pharmaceuticals. Data on file [LCZ15-C025-282] October 2015.

Date of preparation: March 2016 ENT16-C022d